Study on circulating tumor cell counts in prostate cancer – Advanced Prostate Cancer Consensus Conference

Advanced Prostate Cancer Consensus Conference posted the following on LinkedIn:

“Circulating Tumor Cell Count and Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer out on JAMA Network Open.

Study aimed to evaluate the prognostic value of circulating tumor cell (CTC) counts in men with metastatic hormone-sensitive Prostate Cancer (mHSPC).

Blood samples were collected at baseline and disease progression, with CTC counts categorized into three groups: 0, 1-4, or 5+ CTCs per 7.5 mL of blood. The findings revealed that men with 5 or more CTCs had significantly worse overall survival (median 27.9 months) and higher risk of disease progression compared to those with fewer CTCs or none

Adding baseline CTC counts to other known prognostic factors improved survival predictions, suggesting CTC count is a valuable biomarker for identifying high-risk patients who may benefit from more aggressive or novel treatment strategies.”

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Authors: Amir Goldkorn, Catherine Tangen, Melissa Plets, Daniel Bsteh, Tong Xu, Jacek K. Pinski, Sue Ingles, Timothy Junius Triche, Gary R. MacVicar, Daniel A. Vaena, Anthony W. Crispino, David James McConkey, Primo N. Lara Jr, Maha H. A. Hussain, David I. Quinn, Tanya B. Dorff, Seth Paul Lerner, Ian Thompson Jr, Neeraj Agarwal.